⁶⁸Ga-FAPI PET/CT在甲状腺髓样癌中诊断效能优于⁶⁸Ga-DOTATATE PET/CT
本文报道一例60岁女性同时性甲状腺乳头状癌与髓样癌患者,在髓样癌病程中出现血清降钙素升高,⁶⁸Ga-DOTATATE显像示轻度摄取的局部区域及骨转移,以及不摄取的淋巴结和肝转移;⁶⁸Ga-FAPI PET/CT检出优于⁶⁸Ga-DOTATATE PET/CT,尤其肝病灶。随后行¹⁷⁷Lu-FAPI-2286放射性配体治疗,未获生化反应但耐受良好。
要点
- ⁶⁸Ga-FAPI PET/CT对晚期MTC转移灶检出优于⁶⁸Ga-DOTATATE PET/CT。
- ¹⁷⁷Lu-FAPI-2286 RLT在本例中耐受良好但未达生化反应。
- FAP靶向诊疗在晚期MTC有诊断优势,RLT方案仍需标准化。
核心结论
- 在晚期甲状腺髓样癌中,⁶⁸Ga-FAPI PET/CT诊断效能优于⁶⁸Ga-DOTATATE PET/CT,尤其对肝转移灶的检出。
- ¹⁷⁷Lu-FAPI-2286放射性配体治疗在本例中耐受良好但未实现生化反应,提示需标准化RLT方案并探索联合治疗策略。
研究设计与样本
- 个案报道:一例60岁女性同时性甲状腺乳头状癌与髓样癌患者,行全甲状腺切除及辅助治疗后,髓样癌病程中出现血清降钙素升高,先后行⁶⁸Ga-DOTATATE与⁶⁸Ga-FAPI PET/CT,并接受¹⁷⁷Lu-FAPI-2286放射性配体治疗。
主要发现
- ⁶⁸Ga-DOTATATE显像示轻度摄取的局部区域及骨转移,以及不摄取的淋巴结和肝转移。
- ⁶⁸Ga-FAPI PET/CT检出优于⁶⁸Ga-DOTATATE PET/CT,尤其在肝病灶。
- ¹⁷⁷Lu-FAPI-2286放射性配体治疗耐受良好,但未达到生化反应。
临床怎么用
- 对晚期MTC患者,可考虑⁶⁸Ga-FAPI PET/CT以改善转移灶(尤其肝转移)的检出。
- FAP靶向放射性配体治疗用于MTC仍需标准化方案及联合策略探索,不宜作为常规推荐。
局限性
- 本文为单个病例报道,结论外推受限。
- 未报告标准化RLT方案及联合治疗策略的具体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 60-year-old woman with synchronous papillary and medullary thyroid carcinomas (MTC) underwent total thyroidectomy and adjuvant therapy. In later course of her MTC disease, an elevation of serum calcitonin prompted 68 Ga-DOTATATE imaging, revealing mildly avid loco-regional and osseous metastases as well as non-avid nodal and hepatic metastases. 68 Ga-FAPI PET/CT demonstrated superior detection compared with 68 Ga-DOTATATE PET/CT, particularly in hepatic lesions. 177 Lu-FAPI-2286 radioligand therapy (RLT) was administered but failed to achieve biochemical response, though it was well tolerated. This case highlights the diagnostic advantage of FAP-targeted imaging in advanced MTC and underscores the need for standardized RLT protocols and exploration of combination therapeutic strategies.
引用
- Saber Tanha A, Elahifard H, Saberifar M, et al. Superior Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT Compared With ⁶⁸Ga-DOTATATE PET/CT in Medullary Thyroid Carcinoma. Clin Nucl Med. 2026. PMID: 41984869. doi:10.1097/RLU.0000000000006455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。